Effects of Exenatide (Byetta®) on Liver Function in Patients With Nonalcoholic Steatohepatitis (NASH)
Status:
Completed
Trial end date:
2010-09-01
Target enrollment:
Participant gender:
Summary
The primary objective is to test the hypothesis that 24 weeks of treatment with exenatide
will improve the histological acitvity of NASH (steatosis,necroinflammation, ballooning),
summarized in the recently introduced NASH-score in patients with normal, impaired or
diabetic glucose tolerance compared to dietary guidance alone.